These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28100965)

  • 1. Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease.
    Pasala T; Hoo JS; Lockhart MK; Waheed R; Sengodan P; Alexander J; Gandhi S
    Tex Heart Inst J; 2016 Dec; 43(6):482-487. PubMed ID: 28100965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
    Larsen SB; Grove EL; Neergaard-Petersen S; Würtz M; Hvas AM; Kristensen SD
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28780510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease.
    Bernlochner I; Jaitner J; Fries V; Dommasch M; Mayer K; Ott I; Langwieser N; Fusaro M; Laugwitz KL; Kastrati A; Ibrahim T
    Vasa; 2016; 45(2):155-61. PubMed ID: 27058802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.
    Kojuri J; Mahmoody Y; Zangbar Sabegh B; Jannati M; Mahboodi A; Khalili A
    Cardiovasc Ther; 2010 Jun; 28(3):147-52. PubMed ID: 20557313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of aspirin and clopidogrel resistance in peripheral arterial disease.
    Guirgis M; Thompson P; Jansen S
    J Vasc Surg; 2017 Nov; 66(5):1576-1586. PubMed ID: 28893489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
    Milionis H; Ntaios G; Papavasileiou V; Spengos K; Manios E; Elisaf M; Vemmos K
    J Stroke Cerebrovasc Dis; 2017 Dec; 26(12):2769-2777. PubMed ID: 28756905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PR interval prolongation in coronary patients or risk equivalent: excess risk of ischemic stroke and vascular pathophysiological insights.
    Chan YH; Hai JJ; Lau KK; Li SW; Lau CP; Siu CW; Yiu KH; Tse HF
    BMC Cardiovasc Disord; 2017 Aug; 17(1):233. PubMed ID: 28836952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease.
    Yeo KK; Armstrong EJ; López JE; Chen DC; Westin GG; Li CS; Anderson D; Hua A; Singapuri A; Amsterdam EA; Chiamvimonvat N; Laird JR
    Catheter Cardiovasc Interv; 2018 Jun; 91(7):1308-1317. PubMed ID: 29411531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Importance of the Mean Platelet Aggregation Degree in Long-term Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation.
    Li Q; Ren X; Yu X; He J; Gao Y; Zhang X; Wu C; Luo Y; Zhang Y; Chen F
    Cardiovasc Ther; 2016 Jun; 34(3):127-37. PubMed ID: 26826703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
    Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
    Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
    Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF
    Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
    Breet NJ; van Werkum JW; Bouman HJ; Kelder JC; Harmsze AM; Hackeng CM; ten Berg JM
    Heart; 2011 Jun; 97(12):983-90. PubMed ID: 21478385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization.
    Sigvant B; Kragsterman B; Falkenberg M; Hasvold P; Johansson S; Thuresson M; Nordanstig J
    J Vasc Surg; 2016 Oct; 64(4):1009-1017.e3. PubMed ID: 27209402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential impact of peripheral endothelial dysfunction on subsequent cardiovascular events following percutaneous coronary intervention between chronic kidney disease (CKD) and non-CKD patients.
    Tabata N; Hokimoto S; Akasaka T; Arima Y; Sakamoto K; Yamamoto E; Tsujita K; Izumiya Y; Yamamuro M; Kojima S; Kaikita K; Ogawa H
    Heart Vessels; 2016 Jul; 31(7):1038-44. PubMed ID: 26164597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Cholinesterase Levels Are Associated With 2-Year Ischemic Outcomes After Angioplasty and Stenting for Peripheral Artery Disease.
    Gremmel T; Wadowski PP; Mueller M; Kopp CW; Koppensteiner R; Panzer S
    J Endovasc Ther; 2016 Oct; 23(5):738-43. PubMed ID: 27328913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
    Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
    J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.